A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
Conditions
Diseases of the Nervous System
Phase II
Volunteers
Health Professionals
What is the purpose of this trial?
The purpose of this study is to assess the efficacy, safety, and tolerability profile of CVL-865 as adjunctive treatment in participants with drug-resistant focal onset seizures.
- Ages18 years - 75 years
- GenderBoth
- Trial withCerevel Therapeutics, LLC
- Start Date07/25/2020
- End Date10/31/2022
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigator
- Last Updated06/19/2022
- Study HIC#2000027109